TrialPath
Recruiting

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

NCT07816666 · AstraZeneca
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)
About this study
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)
Eligibility criteria
Inclusion Criteria: * Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. * Provision of an archival FFPE tumour sample * Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy. * Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment * Participants who received 4-6 cycles of PBC during the induction phase of their current line of treatment. * Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation. * Participants with non-progressive disease upon completion of PBC in their current line of treatment. * Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance). Exclusion Criteria: * Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours. * Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening * Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab) * Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab) * Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)
Study design
Enrollment target: 600 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-24
Estimated completion: 2031-10-30
Last updated: 2026-10-16
Interventions
Drug: Torvutatug samrotecanDrug: Bevacizumab
Primary outcomes
  • • Progression-Free Survival (PFS) (Up to approximately 5 years)
Sponsor
AstraZeneca · industry
With: GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Ventana Medical Systems, Inc
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (124)
Research SiteNot Yet Recruiting
Anchorage, Alaska, United States
Research SiteNot Yet Recruiting
Miami, Florida, United States
Research SiteNot Yet Recruiting
Indianapolis, Indiana, United States
Research SiteNot Yet Recruiting
Shreveport, Louisiana, United States
Research SiteNot Yet Recruiting
Columbia, Maryland, United States
Research SiteNot Yet Recruiting
Ann Arbor, Michigan, United States
Research SiteNot Yet Recruiting
Detroit, Michigan, United States
Research SiteNot Yet Recruiting
Albany, New York, United States
Research SiteWithdrawn
Bay Shore, New York, United States
Research SiteNot Yet Recruiting
Buffalo, New York, United States
Research SiteWithdrawn
Greenlawn, New York, United States
Research SiteWithdrawn
New Hyde Park, New York, United States
Research SiteNot Yet Recruiting
New York, New York, United States
Research SiteNot Yet Recruiting
New York, New York, United States
Research SiteWithdrawn
Rego Park, New York, United States
Research SiteNot Yet Recruiting
Cleveland, Ohio, United States
Research SiteNot Yet Recruiting
Cleveland, Ohio, United States
Research SiteWithdrawn
Columbus, Ohio, United States
Research SiteNot Yet Recruiting
Mayfield Heights, Ohio, United States
Research SiteWithdrawn
Oklahoma City, Oklahoma, United States
Research SiteNot Yet Recruiting
Philadelphia, Pennsylvania, United States
Research SiteNot Yet Recruiting
Willow Grove, Pennsylvania, United States
Research SiteNot Yet Recruiting
Houston, Texas, United States
Research SiteNot Yet Recruiting
Salt Lake City, Utah, United States
Research SiteNot Yet Recruiting
Norfolk, Virginia, United States
Research SiteNot Yet Recruiting
Morgantown, West Virginia, United States
Research SiteNot Yet Recruiting
Auchenflower, Australia
Research SiteNot Yet Recruiting
Blacktown, Australia
Research SiteNot Yet Recruiting
Clayton, Australia
Research SiteNot Yet Recruiting
Liverpool, Australia
Research SiteNot Yet Recruiting
Porto Alegre, Brazil
Research SiteNot Yet Recruiting
São Caetano do Sul, Brazil
Research SiteNot Yet Recruiting
São José do Rio Preto, Brazil
Research SiteNot Yet Recruiting
São José dos Campos, Brazil
Research SiteNot Yet Recruiting
São Paulo, Brazil
Research SiteNot Yet Recruiting
Teresina, Brazil
Research SiteNot Yet Recruiting
Vitória, Brazil
Research SiteNot Yet Recruiting
Abbotsford British Columbia, British Columbia, Canada
Research SiteNot Yet Recruiting
Montreal, Quebec, Canada
Research SiteNot Yet Recruiting
Montreal, Quebec, Canada
Research SiteNot Yet Recruiting
Beijing, China
Research SiteNot Yet Recruiting
Chengdu, China
Research SiteNot Yet Recruiting
Chengdu, China
Research SiteNot Yet Recruiting
Guangdong Province, China
Research SiteNot Yet Recruiting
Guangzhou, China
Research SiteNot Yet Recruiting
Hangzhou, China
Research SiteNot Yet Recruiting
Hangzhou, China
Research SiteNot Yet Recruiting
Nanchang, China
Research SiteWithdrawn
Wuhan, China
Research SiteNot Yet Recruiting
Wuhan, China
Research SiteNot Yet Recruiting
Wuhan, China
Research SiteNot Yet Recruiting
Zhengzhou, China
Research SiteNot Yet Recruiting
Bad Homburg, Germany
Research SiteNot Yet Recruiting
Bonn, Germany
Research SiteNot Yet Recruiting
Brandenburg, Germany
Research SiteNot Yet Recruiting
Dresden, Germany
Research SiteNot Yet Recruiting
Düsseldorf, Germany
Research SiteNot Yet Recruiting
Essen, Germany
Research SiteNot Yet Recruiting
Gütersloh, Germany
Research SiteNot Yet Recruiting
Halle, Germany
Research SiteNot Yet Recruiting
Hamburg, Germany
Research SiteNot Yet Recruiting
Homburg, Germany
Research SiteNot Yet Recruiting
Kassel, Germany
Research SiteNot Yet Recruiting
Mainz, Germany
Research SiteNot Yet Recruiting
Mannheim, Germany
Research SiteNot Yet Recruiting
Münster, Germany
Research SiteNot Yet Recruiting
Schweinfurt, Germany
Research SiteNot Yet Recruiting
Wiesbaden, Germany
Research SiteNot Yet Recruiting
Wuppertal, Germany
Research SiteNot Yet Recruiting
Ahmedabad, India
Research SiteNot Yet Recruiting
Bangalore, India
Research SiteNot Yet Recruiting
Gūrgaon, India
Research SiteNot Yet Recruiting
Kottayam, India
Research SiteNot Yet Recruiting
Madurai, India
Research SiteWithdrawn
Nashik, India
Research SiteNot Yet Recruiting
Nashik, India
Research SiteNot Yet Recruiting
New Delhi, India
Research SiteNot Yet Recruiting
Vadodara, India
Research SiteNot Yet Recruiting
Milan, Italy
Research SiteNot Yet Recruiting
Milan, Italy
Research SiteNot Yet Recruiting
Monza, Italy
Research SiteNot Yet Recruiting
Naples, Italy
Research SiteNot Yet Recruiting
Rome, Italy
Research SiteNot Yet Recruiting
Torino, Italy
Research SiteNot Yet Recruiting
Treviso, Italy
Research SiteNot Yet Recruiting
Chiba, Japan
Research SiteNot Yet Recruiting
Fukuoka, Japan
Research SiteNot Yet Recruiting
Fukushima, Japan
Research SiteNot Yet Recruiting
Gifu, Japan
Research SiteNot Yet Recruiting
Hidaka-shi, Japan
Research SiteNot Yet Recruiting
Ichihara, Japan
Research SiteNot Yet Recruiting
Kagoshima, Japan
Research SiteNot Yet Recruiting
Kobe, Japan
Research SiteNot Yet Recruiting
Kōtoku, Japan
Research SiteNot Yet Recruiting
Kurume-shi, Japan
Research SiteNot Yet Recruiting
Kyoto, Japan
Research SiteNot Yet Recruiting
Minatoku, Japan
Research SiteNot Yet Recruiting
Natori-shi, Japan
Research SiteNot Yet Recruiting
Sagamihara-shi, Japan
Research SiteNot Yet Recruiting
Shinjuku-ku, Japan
Research SiteNot Yet Recruiting
Suita-shi, Japan
Research SiteNot Yet Recruiting
Toyoake-shi, Japan
Research SiteNot Yet Recruiting
Yokohama, Japan
Research SiteNot Yet Recruiting
Goyang-si, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteRecruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
A Coruña, Spain
Research SiteNot Yet Recruiting
Barakaldo, Spain
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Granollers, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Kaohsiung City, Taiwan
Research SiteNot Yet Recruiting
Taichung, Taiwan
Research SiteRecruiting
Taichung, Taiwan
Research SiteRecruiting
Tainan, Taiwan
Research SiteNot Yet Recruiting
Taipei, Taiwan
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Hat Yai, Thailand
Research SiteNot Yet Recruiting
Muang, Thailand